Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04526834 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma
A Phase 1 study of Diffuse Large B Cell Lymphoma and Peripheral T-Cell Lymphoma, sponsored by Tessa Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
- 4
- Study locations
NCT04526834 is a Phase 1 study of Diffuse Large B Cell Lymphoma and Peripheral T-Cell Lymphoma that is active but no longer recruiting, run by Tessa Therapeutics. The registered enrollment target is 21 participants, below the 218-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (90% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT04526834, a Phase 1 study of Diffuse Large B Cell Lymphoma and Peripheral T-Cell Lymphoma, is active but no longer recruiting, sponsored by Tessa Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a phase 1 study to evaluate safety and dose-limiting toxicity of autologous CD30.CAR-T in subjects with relapsed or refractory CD30+ Non-Hodgkin Lymphoma
Conditions Studied
Interventions
- DRUG CD30.CAR-T
Study Locations (4)
Texas
- Baylor College of Medicine - Houston
- The University of Texas MD Anderson Cancer Centre - Houston
California
- City of Hope - Duarte
Tennessee
- Sarah Cannon Research Institute - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2021-09-08 |
| Est. Completion | 2036-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04526834
The ClinicalTrials.gov registry entry for NCT04526834 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 218-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (90% lower). The listed sponsor is Tessa Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Diffuse Large B Cell Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which CD30.CAR-T is the first listed.
NCT04526834 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Texas, California, Tennessee.
Frequently Asked Questions
What is clinical trial NCT04526834 about?
NCT04526834 is a clinical study titled "Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma". This is a phase 1 study to evaluate safety and dose-limiting toxicity of autologous CD30.CAR-T in subjects with relapsed or refractory CD30+ Non-Hodgkin Lymphoma
What is the current status of trial NCT04526834?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2021-09-08. Estimated completion is 2036-03.
What conditions does trial NCT04526834 study?
This clinical trial studies the following conditions: Diffuse Large B Cell Lymphoma, Peripheral T-Cell Lymphoma, Anaplastic Large Cell Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL), Extranodal NK/T-cell Lymphoma.
What interventions are being tested in trial NCT04526834?
The interventions under investigation include: CD30.CAR-T (DRUG).
Who is sponsoring clinical trial NCT04526834?
This trial is sponsored by Tessa Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04526834 being conducted?
This trial has 4 study locations across California, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diffuse Large B Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
RECRUITING · Phase 1
-
LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
RECRUITING · Phase 1
-
A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas
RECRUITING · Phase 1
-
Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.